Horstink M W, Zijlmans J C, Pasman J W, Berger H J, van't Hof M A
Department of Neurology, University of Nijmegen, The Netherlands.
J Neurol Neurosurg Psychiatry. 1990 Mar;53(3):224-6. doi: 10.1136/jnnp.53.3.224.
Fifty four patients with idiopathic Parkinson's disease receiving levodopa therapy were studied. Thirty three of these patients displayed peak-dose dyskinesia. Neither the duration of Parkinson's disease nor the duration of levodopa therapy discriminated between patients with and patients without peak-dose dyskinesia. Consequently, these criteria could not determine whether the first appearance of peak-dose dyskinesia depends on the duration of Parkinson's disease--a factor that is related to the severity of the disease--or on the duration of levodopa therapy. A subgroup of nineteen patients with unilateral or unequivocally asymmetrical peak-dose dyskinesia was examined 12 hours after withdrawal of levodopa. A levodopa testdose provoked unilateral or unilateral preponderant peak-dose dyskinesia which always involved the most severely affected side and which also happened to be the side of onset of the disease. This demonstrates that the severity of Parkinson's disease is the main risk factor for peak-dose dyskinesia.
对54例接受左旋多巴治疗的特发性帕金森病患者进行了研究。其中33例患者出现剂峰异动症。帕金森病的病程和左旋多巴治疗的病程均无法区分有剂峰异动症的患者和无剂峰异动症的患者。因此，这些标准无法确定剂峰异动症的首次出现是取决于与疾病严重程度相关的帕金森病病程，还是取决于左旋多巴治疗的病程。对19例有单侧或明确不对称剂峰异动症的患者亚组在停用左旋多巴12小时后进行了检查。一次左旋多巴试验剂量诱发了单侧或单侧优势的剂峰异动症，其总是累及受影响最严重的一侧，而这一侧恰好也是疾病的起病侧。这表明帕金森病的严重程度是剂峰异动症的主要危险因素。
